Literature DB >> 22261816

Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

K F Hui1, Dona N Ho, C M Tsang, Jaap M Middeldorp, George S W Tsao, Alan K S Chiang.   

Abstract

Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr virus (EBV). We reported that suberoylanilide hydroxamic acid (SAHA) induced EBV lytic cycle in EBV-positive gastric carcinoma cells and mediated enhanced cell death. However, expression of EBV lytic proteins was thought to exert antiapoptotic effect in EBV-infected cells. Here, we examined the in vitro and in vivo effects of SAHA on EBV lytic cycle induction in NPC cells and investigated the cellular consequences. Micromolar concentrations of SAHA significantly induced EBV lytic cycle in EBV-positive NPC cells. Increased apoptosis and proteolytic cleavage of poly(ADP-ribose) polymerase and caspase-3, -7 and -9 in EBV-positive versus EBV-negative NPC cells were observed. More than 85% of NPC cells expressing immediate-early (Zta), early (BMRF1) or late (gp350/220) lytic proteins coexpressed cleaved caspase-3. Tracking of expression of EBV lytic proteins and cleaved caspase-3 over time demonstrated that NPC cells proceeded to apoptosis following EBV lytic cycle induction. Inhibition of EBV DNA replication and late lytic protein expression by phosphonoformic acid did not impact on SAHA's induced cell death in NPC, indicating that early rather than late phase of EBV lytic cycle contributed to the apoptotic effect. In vivo effects of SAHA on EBV lytic cycle induction and tumor growth suppression were also observed in NPC xenografts in nude mice. Taken together, our data indicated that activation of lytic cycle from latent cycle of EBV by SAHA leads to apoptosis and tumor growth suppression of NPC thereby providing experimental evidence for virus-targeted therapy against EBV-positive cancer.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261816     DOI: 10.1002/ijc.27439

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Lysine-specific post-translational modifications of proteins in the life cycle of viruses.

Authors:  Anna P Loboda; Surinder M Soond; Mauro Piacentini; Nickolai A Barlev
Journal:  Cell Cycle       Date:  2019-07-10       Impact factor: 4.534

2.  B Cell Receptor Activation and Chemical Induction Trigger Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Reactivation.

Authors:  Kun Zhang; Dong-Wen Lv; Renfeng Li
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

3.  Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication.

Authors:  Yuqing Li; Xubing Long; Lu Huang; Mengtian Yang; Yan Yuan; Yan Wang; Henri-Jacques Delecluse; Ersheng Kuang
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

Review 4.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

5.  Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.

Authors:  Mélanie Gressette; Benjamin Vérillaud; Anne-Sophie Jimenez-Pailhès; Hélène Lelièvre; Kwok-Wai Lo; François-Régis Ferrand; Charles-Henry Gattolliat; Anne Jacquet-Bescond; Laurence Kraus-Berthier; Stéphane Depil; Pierre Busson
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Authors:  Mohammed N A Siddiquey; Hikaru Nakagawa; Seiko Iwata; Tetsuhiro Kanazawa; Michio Suzuki; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2014-05-13       Impact factor: 6.716

7.  EBV reactivation as a target of luteolin to repress NPC tumorigenesis.

Authors:  Chung-Chun Wu; Chih-Yeu Fang; Hui-Yu Hsu; Hsin-Ying Chuang; Yu-Jhen Cheng; Yen-Ju Chen; Sheng-Ping Chou; Sheng-Yen Huang; Su-Fang Lin; Yao Chang; Ching-Hwa Tsai; Jen-Yang Chen
Journal:  Oncotarget       Date:  2016-04-05

8.  Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies.

Authors:  Chung King Choi; Dona N Ho; Kwai Fung Hui; Richard Y Kao; Alan K S Chiang
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

Review 9.  Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.

Authors:  Susanna Hilda Hutajulu; Johan Kurnianda; I Bing Tan; Jaap M Middeldorp
Journal:  Ther Clin Risk Manag       Date:  2014-09-05       Impact factor: 2.423

Review 10.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.